Three Different Radiation Therapy Regimens in Treating Patients with Limited-Stage Small Cell Lung Cancer Receiving Cisplatin or Carboplatin and Etoposide
Inclusion Criteria
- Histologically or cytologically confirmed small cell lung cancer
- Limited stage disease patients, with disease restricted to one hemithorax with regional lymph node metastases, including ipsilateral hilar, ipsilateral and contralateral mediastinal, and ipsilateral supraclavicular lymph nodes * Patients with disease involvement of the contralateral hilar or supraclavicular lymph nodes are not eligible * Patients with pleural effusions that are visible on plain chest radiographs, whether cytologically positive or not, are not eligible unless they have a negative thoracentesis * Patients with cytologically positive pleural or pericardial fluid, regardless of the appearance on plain x-ray, are not eligible
- Patients must have measurable disease, which includes lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 2 cm with conventional techniques or as >= 1 cm with spiral computed tomography (CT) scan
- Patients may have received one and only one cycle of chemotherapy prior to enrolling on Cancer and Leukemia Group B (CALGB) 30610, which must have included carboplatin or cisplatin and etoposide; if a patient has had one cycle of cisplatin (or carboplatin)/etoposide prior to registration, the patient must have had all of the prior to registration tests prior to starting their first cycle of chemotherapy; additionally, these patients also must have met all of the eligibility criteria prior to receiving the first cycle of chemotherapy; registration to CALGB 30610 must take place within 7-21 days after the start of the non-protocol therapy; failing to do all of the above will make the patient NOT eligible for CALGB 30610
- No prior radiotherapy or chemotherapy (except for the chemotherapy described in the bullet above) for small cell lung cancer (SCLC)
- No prior mediastinal or thoracic radiotherapy
- Patients with complete surgical resection of disease are not eligible
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) = 0-2
- No patients that are known to be pregnant or nursing
- Granulocytes >= 1,500/ul
- Platelet count >= 100,000/ul
- Total bilirubin =< 1.5 x upper limit of normal (ULN)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2.0 x ULN
- Serum creatinine =< 1.5 times ULN OR calculated creatinine clearance >= 70 mL/min
Alabama
Birmingham
Mobile
Alaska
Anchorage
Fairbanks
Arizona
Scottsdale
Tucson
Arkansas
Hot Springs
Jonesboro
Little Rock
Rogers
California
Antioch
Arroyo Grande
Auburn
Bakersfield
Berkeley
Burbank
Burlingame
Cameron Park
Castro Valley
Clovis
Dublin
El Segundo
Emeryville
Fremont
Fresno
Greenbrae
La Jolla
Los Angeles
Martinez
Marysville
Merced
Modesto
Mountain View
Novato
Oakland
Palo Alto
Pleasanton
Pomona
Redwood City
Richmond
Rohnert Park
Roseville
Sacramento
Saint Helena
San Francisco
San Jose
San Leandro
San Pablo
San Rafael
Santa Clara
Santa Cruz
Santa Rosa
South San Francisco
Stockton
Sunnyvale
Truckee
Vacaville
Vallejo
Walnut Creek
Colorado
Aurora
Boulder
Colorado Springs
Denver
Durango
Englewood
Golden
Grand Junction
Greeley
Greenwood Village
Lakewood
Littleton
Lone Tree
Longmont
Loveland
Parker
Pueblo
Thornton
Wheat Ridge
Connecticut
Hartford
Delaware
Lewes
Newark
Rehoboth Beach
Seaford
Wilmington
Florida
Altamonte Springs
Aventura
Bradenton
Fort Lauderdale
Fort Walton Beach
Jacksonville
Jacksonville Beach
Jupiter
Kissimmee
Lakewood Ranch
Miami Beach
Orange Park
Orlando
Palatka
Saint Augustine
Tampa
Winter Park
Georgia
Atlanta
Carrollton
Columbus
Gainesville
Savannah
Hawaii
Honolulu
Idaho
Boise
Caldwell
Coeur D'Alene
Emmett
Fruitland
Meridian
Nampa
Post Falls
Sandpoint
Twin Falls
Illinois
Aurora
Bloomington
Canton
Carbondale
Carterville
Carthage
Centralia
Chicago
Danville
Decatur
Effingham
Eureka
Evanston
Galesburg
Glenview
Havana
Highland Park
Kankakee
Kewanee
La Grange
Macomb
Mattoon
Moline
Monmouth
Normal
O'Fallon
Oak Lawn
Ottawa
Pekin
Peoria
Peru
Princeton
Rockford
Skokie
Spring Valley
Springfield
Swansea
Urbana
Yorkville
Indiana
Elkhart
Evansville
Fort Wayne
Indianapolis
Kokomo
La Porte
Mishawaka
Muncie
Newburgh
Plymouth
South Bend
Westville
Iowa
Bettendorf
Clive
Creston
Des Moines
Sioux City
West Des Moines
Kansas
Chanute
Dodge City
El Dorado
Fort Scott
Independence
Kingman
Lawrence
Lenexa
Liberal
Manhattan
McPherson
Newton
Overland Park
Parsons
Pratt
Salina
Topeka
Wellington
Wichita
Winfield
Kentucky
Lexington
Louisville
Owensboro
Louisiana
Baton Rouge
Covington
Houma
Metairie
New Orleans
Maine
Lewiston
Maryland
Baltimore
Bethesda
Easton
Elkton
Ocean Pines
Randallstown
Rockville
Salisbury
Westminster
Massachusetts
Boston
Brighton
Fitchburg
Milford
South Weymouth
Worcester
Michigan
Ann Arbor
Battle Creek
Brighton
Canton
Caro
Chelsea
Clarkston
Dearborn
Detroit
East China
Escanaba
Farmington Hills
Flint
Grand Rapids
Grosse Pointe Woods
Iron Mountain
Jackson
Kalamazoo
Lansing
Livonia
Macomb Township
Marlette
Mount Clemens
Muskegon
Niles
Norton Shores
Novi
Pontiac
Port Huron
Reed City
Rochester Hills
Royal Oak
Saginaw
Saint Joseph
Southfield
Sterling Heights
Traverse City
Troy
Warren
West Branch
Wyoming
Ypsilanti
Minnesota
Bemidji
Burnsville
Coon Rapids
Edina
Fridley
Hutchinson
Maple Grove
Maplewood
Minneapolis
Monticello
New Ulm
Robbinsdale
Rochester
Saint Cloud
Saint Louis Park
Saint Paul
Shakopee
Stillwater
Waconia
Willmar
Woodbury
Wyoming
Mississippi
Columbus
Grenada
Jackson
New Albany
Oxford
Pascagoula
Southhaven
Missouri
Bonne Terre
Cape Girardeau
Chesterfield
Columbia
Creve Coeur
Independence
Jefferson City
Kansas City
Lee's Summit
Liberty
Saint Joseph
Saint Louis
Saint Peters
Sainte Genevieve
Sullivan
Sunset Hills
Montana
Anaconda
Billings
Bozeman
Butte
Great Falls
Helena
Kalispell
Missoula
Nebraska
Grand Island
Kearney
Lincoln
Norfolk
North Platte
Omaha
Papillion
Scottsbluff
Nevada
Carson City
Henderson
Las Vegas
Reno
New Hampshire
Concord
Exeter
Lebanon
Manchester
Nashua
New Jersey
Basking Ridge
Camden
Middletown
Montvale
Mount Holly
Paramus
Ridgewood
Sparta
Voorhees
Westwood
New Mexico
Albuquerque
New York
Bronx
Buffalo
Canandiaqua
Commack
Elmira
Glens Falls
New York
Rochester
Sleepy Hollow
Stony Brook
Syracuse
Uniondale
West Harrison
North Carolina
Asheville
Brevard
Chapel Hill
Charlotte
Clinton
Durham
Franklin
Goldsboro
Greenville
Hendersonville
Huntersville
Jacksonville
Kenansville
Kernersville
Kinston
Marion
Matthews
Mooresville
Mount Airy
Pinehurst
Raleigh
Richlands
Salisbury
Spruce Pine
Statesville
Stateville
Supply
Thomasville
Wilkesboro
Wilmington
Winston-Salem
North Dakota
Bismarck
Fargo
Grand Forks
Minot
Ohio
Akron
Barberton
Beachwood
Belpre
Canton
Chardon
Chillicothe
Cincinnati
Cleveland
Columbus
Dayton
Delaware
Elyria
Independence
Lancaster
Mansfield
Marietta
Marion
Mayfield Heights
Medina
Mentor
Middleburg Heights
Mount Vernon
Newark
Parma
Portsmouth
Ravenna
Salem
Sandusky
Springfield
Strongsville
Sylvania
Toledo
WPAFB
West Chester
Westerville
Westlake
Wooster
Zanesville
Oklahoma
Oklahoma City
Tulsa
Oregon
Baker City
Bend
Clackamas
Coos Bay
Milwaukie
Newberg
Ontario
Oregon City
Portland
The Dalles
Pennsylvania
Abington
Allentown
Beaver
Bethlehem
Broomall
Bryn Mawr
Darby
Drexel Hill
Dunmore
East Stroudsburg
Ephrata
Gettysburg
Glen Mills
Greensburg
Hanover
Hershey
Johnstown
Lebanon
McKeesport
Meadowbrook
Media
Milford
Moon Township
Natrona Heights
New Castle
Paoli
Philadelphia
Pittsburgh
Seneca
Uniontown
Upland
Washington
West Reading
Wynnewood
York
Puerto Rico
San Juan
South Carolina
Anderson
Boiling Springs
Charleston
Easley
Gaffney
Georgetown
Greenville
Greenwood
Greer
Lancaster
Myrtle Beach
Rock Hill
Seneca
Spartanburg
Union
South Dakota
Sioux Falls
Tennessee
Bristol
Chattanooga
Cookeville
Johnson City
Kingsport
Knoxville
Maryville
Memphis
Texas
Amarillo
Beaumont
Bryan
Conroe
Dallas
Galveston
Houston
League City
San Antonio
Sugar Land
Utah
Cedar City
Logan
Murray
Ogden
Provo
Riverton
Saint George
Salt Lake City
Vermont
Saint Johnsbury
Virginia
Bristol
Norton
Washington
Aberdeen
Anacortes
Auburn
Bellevue
Bellingham
Bremerton
Burien
Centralia
Edmonds
Everett
Gig Harbor
Issaquah
Kennewick
Lacey
Longview
Puyallup
Renton
Seattle
Sedro-Woolley
Shelton
Spokane
Spokane Valley
Tacoma
Vancouver
Walla Walla
Yakima
Yelm
West Virginia
Bridgeport
Charleston
Morgantown
Parkersburg
Wheeling
Wisconsin
Antigo
Appleton
Brookfield
Eau Claire
Fond Du Lac
Franklin
Green Bay
Johnson Creek
La Crosse
Madison
Marinette
Marshfield
Milwaukee
Minocqua
New Richmond
Oconto Falls
Oshkosh
Racine
Rhinelander
Rice Lake
Stevens Point
Sturgeon Bay
Wausau
Weston
Wisconsin Rapids
Wyoming
Casper
Cheyenne
Cody
Sheridan
Israel
Petach Tikva
Korea, Republic of
Seoul
PRIMARY OBJECTIVES:
I. To determine whether administering high-dose thoracic radiotherapy, 70 Gray (Gy) (2 Gy once daily over 7 weeks) or 61.2 Gy (1.8 Gy once daily for 16 days followed by 1.8 Gy twice daily for 9 days), will improve median and 2-year survival compared with 45 Gy (1.5 Gy twice daily over 3 weeks) in patients with limited-stage small cell lung cancer.
SECONDARY OBJECTIVES:
I. To compare treatment-related toxic effects of thoracic radiotherapy regimens in patients with limited-stage small cell lung cancer.
II. To compare response rates, failure-free survival, and toxicity of thoracic radiotherapy regimens in patients with limited-stage small cell lung cancer.
III. To compare rates of local relapse, distant metastases, and brain metastases with these regimens.
IV. To compare patients’ quality of life between these treatment regimens in terms of their physical symptoms, physical functioning and psychological state.
V. To describe the patterns of use of thoracic intensity modulated radiation therapy (IMRT) in patients with limited stage small cell lung cancer.
VI. To examine blood-based biomarkers of response and resistance to cisplatin (or carboplatin) and etoposide.
VII. To evaluate the correspondence between increases in plasma pro-gastrin-releasing peptide (proGRP) concentrations and disease progression/recurrence.
VIII. To evaluate the potential for plasma proGRP concentrations at baseline, after each cycle of chemotherapy and at first evaluation following completion of chemotherapy to predict progression-free survival (PFS) and overall survival (OS).
IX. To evaluate the correspondence between longitudinal decreases in plasma proGRP concentrations and clinical response.
OUTLINE:
PART 1: Patients are randomized to 1 of 3 treatment arms.
ARM I: Patients undergo standard-dose (45 Gy given in 30 treatments) thoracic radiotherapy twice daily (BID), 5 days a week, for 3 weeks. Patients also receive cisplatin intravenously (IV) or carboplatin IV on day 1 and etoposide IV on days 1, 2, and 3.
ARM II: Patients undergo higher-dose (70 Gy given in 35 treatments) thoracic radiotherapy once daily (QD), 5 days a week, for 7 weeks. Patients also receive cisplatin or carboplatin and etoposide as in Arm I.
ARM III (CLOSED TO ACCRUAL AS OF 3/10/13): Patients undergo higher-dose (61.2 Gy given in 34 treatments) thoracic radiotherapy QD, 5 days a week, during the initial 16 days (approximately 3 weeks) of treatment and then BID, 5 days a week, for the final 9 days (approximately 2 weeks) of treatment. Patients also receive cisplatin or carboplatin and etoposide as in Arm I.
In all arms, treatment with cisplatin or carboplatin and etoposide repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
PART 2: An interim analysis, conducted after accrual of 30 patients per arm, selected one experimental arm based upon a comparison of treatment-related toxicity. The most toxic experimental arm (Arm C) was discontinued, and the trial continued comparing standard therapy (Arm I) to the selected experimental regimen (Arm II).
PROPHYLACTIC CRANIAL IRRADIATION (PCI): Within 3-6 weeks after completion of chemotherapy, patients with a complete tumor response (complete response [CR]) or near complete response (very good partial response [PR]) with only residual chest abnormalities of indeterminate nature are eligible to undergo prophylactic radiotherapy to the brain QD, 5 days a week, for 2 weeks. Patients with a response to therapy that is less than CR or very good PR may undergo PCI at the investigator’s discretion.
After completion of study treatment, patients are followed up at least every 3 months for 2 years, every 6 months for 3 years, and then annually for 5 years or until disease progression. At disease progression, patients are followed up every 6 months.
Trial Phase Phase III
Trial Type Treatment
Lead Organization
Alliance for Clinical Trials in Oncology
Principal Investigator
Jeffrey Alan Bogart
- Primary ID CALGB-30610
- Secondary IDs NCI-2009-00470, CALGB 30610/RTOG 0538, CDR0000588879, RTOG 0538
- Clinicaltrials.gov ID NCT00632853